Longitudinal assessment of health-related quality of life, sleep quality, and gustation in patients with advanced urothelial carcinoma receiving late-line enfortumab vedotin monotherapy

Makito Miyake, Nobutaka Nishimura, Yuki Oda, Takuto Shimizu, Takuya Owari, Kota Iida, Yasushi Nakai, Nobumichi Tanaka, Kiyohide Fujimoto

Open source

DOI
10.1007/s10147-025-02953-5
Published
2025-12-28
Container
International Journal of Clinical Oncology
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s10147-025-02953-5,
  title = {Longitudinal assessment of health-related quality of life, sleep quality, and gustation in patients with advanced urothelial carcinoma receiving late-line enfortumab vedotin monotherapy},
  author = {Makito Miyake and Nobutaka Nishimura and Yuki Oda and Takuto Shimizu and Takuya Owari and Kota Iida and Yasushi Nakai and Nobumichi Tanaka and Kiyohide Fujimoto},
  year = {2025},
  journal = {International Journal of Clinical Oncology},
  doi = {10.1007/s10147-025-02953-5},
  url = {https://doi.org/10.1007/s10147-025-02953-5}
}

RIS

TY  - JOUR
TI  - Longitudinal assessment of health-related quality of life, sleep quality, and gustation in patients with advanced urothelial carcinoma receiving late-line enfortumab vedotin monotherapy
AU  - Makito Miyake
AU  - Nobutaka Nishimura
AU  - Yuki Oda
AU  - Takuto Shimizu
AU  - Takuya Owari
AU  - Kota Iida
AU  - Yasushi Nakai
AU  - Nobumichi Tanaka
AU  - Kiyohide Fujimoto
PY  - 2025
JO  - International Journal of Clinical Oncology
DO  - 10.1007/s10147-025-02953-5
UR  - https://doi.org/10.1007/s10147-025-02953-5
ER  - 

APA

Miyake, M., Nishimura, N., Oda, Y., Shimizu, T., Owari, T., Iida, K., Nakai, Y., Tanaka, N., & Fujimoto, K. (2025). Longitudinal assessment of health-related quality of life, sleep quality, and gustation in patients with advanced urothelial carcinoma receiving late-line enfortumab vedotin monotherapy. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-025-02953-5

Source records